WO1996012734A1 - Preparation vaccinale obtenue a partir de bacteries cultivees dans des milieux riches en fer - Google Patents
Preparation vaccinale obtenue a partir de bacteries cultivees dans des milieux riches en fer Download PDFInfo
- Publication number
- WO1996012734A1 WO1996012734A1 PCT/SE1995/001251 SE9501251W WO9612734A1 WO 1996012734 A1 WO1996012734 A1 WO 1996012734A1 SE 9501251 W SE9501251 W SE 9501251W WO 9612734 A1 WO9612734 A1 WO 9612734A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine
- bacteria
- iron
- effective against
- vaccine according
- Prior art date
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 60
- 229960005486 vaccine Drugs 0.000 title claims abstract description 56
- 241000894006 Bacteria Species 0.000 title claims abstract description 30
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title abstract description 19
- 239000002609 medium Substances 0.000 claims abstract description 18
- 239000001963 growth medium Substances 0.000 claims abstract description 10
- 230000000050 nutritive effect Effects 0.000 claims abstract description 7
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 6
- 238000012258 culturing Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims abstract 9
- 241000251468 Actinopterygii Species 0.000 claims description 23
- 244000052769 pathogen Species 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 241000607598 Vibrio Species 0.000 claims description 4
- 241000607528 Aeromonas hydrophila Species 0.000 claims description 3
- 241001517024 Photobacterium damselae subsp. piscicida Species 0.000 claims description 3
- 241000607525 Aeromonas salmonicida Species 0.000 claims description 2
- 241000949274 Edwardsiella ictaluri Species 0.000 claims description 2
- 241000607471 Edwardsiella tarda Species 0.000 claims description 2
- 241000604777 Flavobacterium columnare Species 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 206010047400 Vibrio infections Diseases 0.000 claims 2
- 244000037640 animal pathogen Species 0.000 claims 2
- 244000052637 human pathogen Species 0.000 claims 2
- 241000122170 Aliivibrio salmonicida Species 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241000604754 Flexibacter Species 0.000 claims 1
- 206010034107 Pasteurella infections Diseases 0.000 claims 1
- 241000607734 Yersinia <bacteria> Species 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 201000005115 pasteurellosis Diseases 0.000 claims 1
- 101710116435 Outer membrane protein Proteins 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000002738 chelating agent Substances 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000010633 broth Nutrition 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000017033 Porins Human genes 0.000 description 5
- 108010013381 Porins Proteins 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 101001056675 Klebsiella pneumoniae Ferric aerobactin receptor Proteins 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 101150020337 TSB2 gene Proteins 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- PZZHMLOHNYWKIK-UHFFFAOYSA-N eddha Chemical compound C=1C=CC=C(O)C=1C(C(=O)O)NCCNC(C(O)=O)C1=CC=CC=C1O PZZHMLOHNYWKIK-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical class [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 239000000589 Siderophore Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009313 farming Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229940016590 sarkosyl Drugs 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical group [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000382842 Flavobacterium psychrophilum Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000544286 Vibrio anguillarum Species 0.000 description 1
- 241001148129 Yersinia ruckeri Species 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- -1 ethylenediamino diacetic acid Chemical compound 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 150000004698 iron complex Chemical class 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 244000000003 plant pathogen Species 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to improved vaccines and the preparation of vac- cines active against bacterial diseases, whereby a pathogenic bacteria is culti ⁇ vated, and a vaccine is prepared from the cultivated bacteria or its expression components present in the growth medium.
- NaCI (designated TSB2) was prepared and aliquoted 250 ml each into 500 ml 5 conical flasks, which were autoclaved at 121°C for 15 min. The flasks were allowed to cool whereupon the following filter sterilized additions were made aseptically into separate flasks:
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention se rapporte à un vaccin amélioré et à son procédé de préparation. Ce vaccin amélioré contre les maladies d'origine bactérienne est obtenu d'une culture de bactéries produisant une bactérine dans un milieu nutritif contenant des sources de fer à des niveaux dépassant ceux des milieux généralement utilisés jusqu'ici à cet effet. Le vaccin est ensuite préparé à partir des bactéries cultivées et/ou de leurs parties constitutives et/ou de constituants exprimés par ces bactéries et présents dans le milieu de croissance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU38210/95A AU3821095A (en) | 1994-10-24 | 1995-10-23 | Vaccine preparation recovered from bacteria grown in iron-rich media |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9403636-5 | 1994-10-24 | ||
| SE9403636A SE9403636D0 (sv) | 1994-10-24 | 1994-10-24 | Vaccine preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996012734A1 true WO1996012734A1 (fr) | 1996-05-02 |
Family
ID=20395723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/SE1995/001251 WO1996012734A1 (fr) | 1994-10-24 | 1995-10-23 | Preparation vaccinale obtenue a partir de bacteries cultivees dans des milieux riches en fer |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU3821095A (fr) |
| SE (1) | SE9403636D0 (fr) |
| WO (1) | WO1996012734A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2115550A1 (es) * | 1996-10-14 | 1998-06-16 | Univ Santiago Compostela | Vacuna anti-pasteurella piscicida (di)para la prevencion de la enfermedad pasteurelosis en dorada y lubina y procedimiento de obtencion. . |
| WO2001010459A3 (fr) * | 1999-08-07 | 2001-05-10 | Aqua Health Europ Ltd | Vaccin |
| WO2005014629A3 (fr) * | 2003-07-29 | 2005-11-17 | Novartis Ag | Proteine issue de photobacterium damselae et utilisation de celle-ci |
-
1994
- 1994-10-24 SE SE9403636A patent/SE9403636D0/xx unknown
-
1995
- 1995-10-23 AU AU38210/95A patent/AU3821095A/en not_active Abandoned
- 1995-10-23 WO PCT/SE1995/001251 patent/WO1996012734A1/fr active Application Filing
Non-Patent Citations (2)
| Title |
|---|
| JOURNAL OF GENERAL MICROBIOLOGY, Volume 138, 1992, R.L. DAVIES et al., "Outer-Membrane Protein and Lipopolysaccharide Variation in Pasteurella Haemolytica Serotype A1 Under Different Growth Conditions", pages 909-922. * |
| VETERINARY MICROBIOLOGY, Volume 41, 1994, DONNA M. GATEWOOD et al., "Growth-Condition Dependent Expression of Pasteurella Haemolytica A1 Outer Membrane Proteins, Capsule and Leukotoxin", pages 221-233. * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2115550A1 (es) * | 1996-10-14 | 1998-06-16 | Univ Santiago Compostela | Vacuna anti-pasteurella piscicida (di)para la prevencion de la enfermedad pasteurelosis en dorada y lubina y procedimiento de obtencion. . |
| WO2001010459A3 (fr) * | 1999-08-07 | 2001-05-10 | Aqua Health Europ Ltd | Vaccin |
| JP2003506412A (ja) * | 1999-08-07 | 2003-02-18 | ノバルテイス・アクチエンゲゼルシヤフト | ワクチン |
| JP2011207888A (ja) * | 1999-08-07 | 2011-10-20 | Novartis Ag | ワクチン |
| JP4831905B2 (ja) * | 1999-08-07 | 2011-12-07 | ノバルティス アーゲー | ワクチン |
| WO2005014629A3 (fr) * | 2003-07-29 | 2005-11-17 | Novartis Ag | Proteine issue de photobacterium damselae et utilisation de celle-ci |
| JP2007526755A (ja) * | 2003-07-29 | 2007-09-20 | ノバルティス アクチエンゲゼルシャフト | フォトバクテリウム・ダムセラの蛋白質およびその使用 |
| JP4881731B2 (ja) * | 2003-07-29 | 2012-02-22 | ノバルティス アーゲー | フォトバクテリウム・ダムセラの蛋白質およびその使用 |
| US8197827B2 (en) | 2003-07-29 | 2012-06-12 | Novartis Ag | Protein from Photobacterium damselae and use thereof |
| US8343507B2 (en) | 2003-07-29 | 2013-01-01 | Novartis Ag | Protein from Photobacterium damselae and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3821095A (en) | 1996-05-15 |
| SE9403636D0 (sv) | 1994-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1139663A (fr) | Vaccin contre la diarrhee causee par e. coli | |
| US8926980B2 (en) | Compositions against bacterial toxins | |
| US5616328A (en) | Method of preparing gram-negative bacterial vaccines | |
| JPH0840932A (ja) | スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法 | |
| US4285931A (en) | E. coli enterotoxin vaccine for veterinary and human use | |
| US4220584A (en) | E. coli enterotoxin vaccine for veterinary and human use | |
| JP2718518B2 (ja) | マイコプラズマワクチン | |
| EP0625190B1 (fr) | Nouvelle bacterie provoquant des maladies chez les volailles et vaccin derive de cette bacterie | |
| WO1996012734A1 (fr) | Preparation vaccinale obtenue a partir de bacteries cultivees dans des milieux riches en fer | |
| EP0374178A1 (fr) | Procede de preparation de vaccins veterinaires acellulaires contre des bacilles pathogenes non-enteriques gram-negatifs. | |
| US4136181A (en) | Vaccines against oedema disease of piglets | |
| GB2023420A (en) | Preparations containing antigen from pasteurella haemolytica | |
| US20040170652A1 (en) | Saponin inactivated mycoplasma vaccine | |
| CN100563708C (zh) | 具有交叉保护力的革兰氏阴性病原菌灭活疫苗的制备方法 | |
| RU2109519C1 (ru) | Способ изготовления вакцины против некробактериоза животных | |
| Matsuo et al. | Suppression of immunoresponses to Haemophilus gallinarum with nonviable Mycoplasma gallisepticum in chickens | |
| JP2721218B2 (ja) | ブタ赤痢ワクチン | |
| CA1188220A (fr) | Preparation d'une neurotoxine d'e. coli detoxifiee et produits ainsi obtenus | |
| RU1149467C (ru) | Вакцина против колибактериоза молодняка крупного рогатого скота и овец | |
| US3980523A (en) | Method of propagating microorganisms | |
| EP0563288B1 (fr) | Immunopotentialisation de vaccins, notamment de vaccins contre la pleuropneumonie porcine | |
| JP4081515B2 (ja) | 魚類の腸球菌症用ワクチン | |
| RU1149466C (ru) | Вакцина против колибактериоза поросят | |
| RU2018322C1 (ru) | Вакцина против рожи свиней | |
| KR20050001480A (ko) | 돈단독 예방용 백신과 이를 이용한 혼합백신 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN FI JP MX NO US VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |